|

RE002 T cell Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • Henan Cancer Hospital1

Indications

  • T Cell Therapy1
  • KRAS G12D1
  • Cancer1

Other1 trial

RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.